FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Significance of bone biomarkers determination in the assessment of fracture risk and response to therapy in patients with osteoporosis

Značaj određivanja koštanih biomarkera u proceni rizika od fraktura i praćenju terapije kod pacijenata sa osteoporozom

Thumbnail
2017
2919.pdf (252.7Kb)
Authors
Milić, Anđelka
Đurić, Milena
Gajić, Gordana
Mitrović, Milan
Urošević, Ljiljana
Jovanović, Veljko
Ješić, Budimir
Kovačević, Radmila
Vekić, Jelena
Zeljković, Aleksandra
Stefanović, Aleksandra
Ninić, Ana
Spasojević-Kalimanovska, Vesna
Article (Published version)
Metadata
Show full item record
Abstract
Osteoporosis is characterised by reduced bone mineral density (BMD), increased bone fragility and risk of fractures. We investigated clinical significance of bone turnover biomarkers determination for the prediction of fracture risk and response to therapy. We performed three months follow-up study in 48 women with osteoporosis. During the follow-up period 32 patients were on antiresorptive and 16 patients received anabolic therapy. Serum alkaline phosphatase (ALP), osteocalcin, C-terminal telopeptide of collagen type I and vitamin D were measured before and 3 months after initiation of the therapy. Higher osteocalcin and ALP levels were significantly associated with increased risk of BMD loss. Following antiresorptive therapy levels of C-terminal telopeptide (P lt 0.001) and osteocalcin (P lt 0.001) significantly decreased. Anabolic therapy significantly increased osteocalcin (P lt 0.01). At the study entry 25.5% of the patients had optimal levels of 25(OH)D and 17% had severe vitamin... D deficiency. Vitamin D supplementation during three months improved vitamin D status of the patients (P lt 0.001). In conclusion, our data indicate that osteocalcin and C-terminal telopeptide determination may be useful for BMD loss prediction and monitoring of osteoporosis therapy. This study confirmed importance of vitamin D testing in osteoporosis in order to detect the patients with deficiency and determine the need for supplementation.

Osteoporoza se karakteriše smanjenom mineralnom gustinom kostiju, što povećava fragilnost kostiju i rizik za nastanak fraktura. U ovoj studiji pratili smo 48 pacijentkinja sa osteoporozom tokom tri meseca sa ciljem da utvrdimo značaj određivanja koštanih biomarkera u proceni rizika od fraktura i praćenju terapije osteoporoze. Tokom trajanja studije 32 pacijentkinje su bile na antiresorptivnoj, a 16 na anaboličkoj terapiji. Svim pacijentkinjama odredili smo aktivnost alkalne fosfataze (ALP) i koncentracije osteokalcina, C-terminalnog telopeptida kolagena tip I i vitamina D u serumu pre i tri meseca nakon uvođenja terapije. Sa povećanjem nivoa osteokalcina i ALP rastao je rizik za smanjenje mineralne gustine kostiju (BMD). Antiresorptivna terapija dovela je do značajnog smanjenja koncentracija C-terminalnog telopeptida (P lt 0,001) i osteokalcina (P lt 0,001). Tokom anaboličke terapije nivo osteokalcina je značajno porastao (P lt 0,01). Na početku studije 25,5% pacijentkinja je imalo opt...imalne koncentracije 25(OH)D u serumu, a tešku deficijenciju 17% žena. Nakon 3 meseca suplementacije većina je poboljšala status vitamina D (P lt 0,001). Naši rezultati ukazuju da određivanje osteokalcina i C-terminalnog telopeptida može biti korisno za predviđanje rizika za smanjenje BMD i praćenje efekata terapije osteoporoze. Takođe, potvrđena je važnost određivanja koncentracije 25(OH)D za procenu statusa vitamina D u osteoporozi, u cilju otkrivanja pacijenata sa insuficijencijom i utvrđivanja potrebe za suplementacijom.

Keywords:
osteoporosis / bone biomarkers / vitamin D / therapy monitoring / osteoporoza / koštani biomarkeri / vitamin D / praćenje terapije
Source:
Arhiv za farmaciju, 2017, 67, 3, 196-208
Publisher:
  • Savez farmaceutskih udruženja Srbije, Beograd
Funding / projects:
  • Interactive role of dyslipidemia, oxidative stress and inflammation in atherosclerosis and other diseases: genetic and biochemical markers (RS-175035)

DOI: 10.5937/arhfarm1703196M

ISSN: 0004-1963

Scopus: 2-s2.0-85055026048
[ Google Scholar ]
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/2921
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Milić, Anđelka
AU  - Đurić, Milena
AU  - Gajić, Gordana
AU  - Mitrović, Milan
AU  - Urošević, Ljiljana
AU  - Jovanović, Veljko
AU  - Ješić, Budimir
AU  - Kovačević, Radmila
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Ninić, Ana
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2921
AB  - Osteoporosis is characterised by reduced bone mineral density (BMD), increased bone fragility and risk of fractures. We investigated clinical significance of bone turnover biomarkers determination for the prediction of fracture risk and response to therapy. We performed three months follow-up study in 48 women with osteoporosis. During the follow-up period 32 patients were on antiresorptive and 16 patients received anabolic therapy. Serum alkaline phosphatase (ALP), osteocalcin, C-terminal telopeptide of collagen type I and vitamin D were measured before and 3 months after initiation of the therapy. Higher osteocalcin and ALP levels were significantly associated with increased risk of BMD loss. Following antiresorptive therapy levels of C-terminal telopeptide (P lt 0.001) and osteocalcin (P lt 0.001) significantly decreased. Anabolic therapy significantly increased osteocalcin (P lt 0.01). At the study entry 25.5% of the patients had optimal levels of 25(OH)D and 17% had severe vitamin D deficiency. Vitamin D supplementation during three months improved vitamin D status of the patients (P lt 0.001). In conclusion, our data indicate that osteocalcin and C-terminal telopeptide determination may be useful for BMD loss prediction and monitoring of osteoporosis therapy. This study confirmed importance of vitamin D testing in osteoporosis in order to detect the patients with deficiency and determine the need for supplementation.
AB  - Osteoporoza se karakteriše smanjenom mineralnom gustinom kostiju, što povećava fragilnost kostiju i rizik za nastanak fraktura. U ovoj studiji pratili smo 48 pacijentkinja sa osteoporozom tokom tri meseca sa ciljem da utvrdimo značaj određivanja koštanih biomarkera u proceni rizika od fraktura i praćenju terapije osteoporoze. Tokom trajanja studije 32 pacijentkinje su bile na antiresorptivnoj, a 16 na anaboličkoj terapiji. Svim pacijentkinjama odredili smo aktivnost alkalne fosfataze (ALP) i koncentracije osteokalcina, C-terminalnog telopeptida kolagena tip I i vitamina D u serumu pre i tri meseca nakon uvođenja terapije. Sa povećanjem nivoa osteokalcina i ALP rastao je rizik za smanjenje mineralne gustine kostiju (BMD). Antiresorptivna terapija dovela je do značajnog smanjenja koncentracija C-terminalnog telopeptida (P lt 0,001) i osteokalcina (P lt 0,001). Tokom anaboličke terapije nivo osteokalcina je značajno porastao (P lt 0,01). Na početku studije 25,5% pacijentkinja je imalo optimalne koncentracije 25(OH)D u serumu, a tešku deficijenciju 17% žena. Nakon 3 meseca suplementacije većina je poboljšala status vitamina D (P lt 0,001). Naši rezultati ukazuju da određivanje osteokalcina i C-terminalnog telopeptida može biti korisno za predviđanje rizika za smanjenje BMD i praćenje efekata terapije osteoporoze. Takođe, potvrđena je važnost određivanja koncentracije 25(OH)D za procenu statusa vitamina D u osteoporozi, u cilju otkrivanja pacijenata sa insuficijencijom i utvrđivanja potrebe za suplementacijom.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Significance of bone biomarkers determination in the assessment of fracture risk and response to therapy in patients with osteoporosis
T1  - Značaj određivanja koštanih biomarkera u proceni rizika od fraktura i praćenju terapije kod pacijenata sa osteoporozom
VL  - 67
IS  - 3
SP  - 196
EP  - 208
DO  - 10.5937/arhfarm1703196M
ER  - 
@article{
author = "Milić, Anđelka and Đurić, Milena and Gajić, Gordana and Mitrović, Milan and Urošević, Ljiljana and Jovanović, Veljko and Ješić, Budimir and Kovačević, Radmila and Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Ninić, Ana and Spasojević-Kalimanovska, Vesna",
year = "2017",
abstract = "Osteoporosis is characterised by reduced bone mineral density (BMD), increased bone fragility and risk of fractures. We investigated clinical significance of bone turnover biomarkers determination for the prediction of fracture risk and response to therapy. We performed three months follow-up study in 48 women with osteoporosis. During the follow-up period 32 patients were on antiresorptive and 16 patients received anabolic therapy. Serum alkaline phosphatase (ALP), osteocalcin, C-terminal telopeptide of collagen type I and vitamin D were measured before and 3 months after initiation of the therapy. Higher osteocalcin and ALP levels were significantly associated with increased risk of BMD loss. Following antiresorptive therapy levels of C-terminal telopeptide (P lt 0.001) and osteocalcin (P lt 0.001) significantly decreased. Anabolic therapy significantly increased osteocalcin (P lt 0.01). At the study entry 25.5% of the patients had optimal levels of 25(OH)D and 17% had severe vitamin D deficiency. Vitamin D supplementation during three months improved vitamin D status of the patients (P lt 0.001). In conclusion, our data indicate that osteocalcin and C-terminal telopeptide determination may be useful for BMD loss prediction and monitoring of osteoporosis therapy. This study confirmed importance of vitamin D testing in osteoporosis in order to detect the patients with deficiency and determine the need for supplementation., Osteoporoza se karakteriše smanjenom mineralnom gustinom kostiju, što povećava fragilnost kostiju i rizik za nastanak fraktura. U ovoj studiji pratili smo 48 pacijentkinja sa osteoporozom tokom tri meseca sa ciljem da utvrdimo značaj određivanja koštanih biomarkera u proceni rizika od fraktura i praćenju terapije osteoporoze. Tokom trajanja studije 32 pacijentkinje su bile na antiresorptivnoj, a 16 na anaboličkoj terapiji. Svim pacijentkinjama odredili smo aktivnost alkalne fosfataze (ALP) i koncentracije osteokalcina, C-terminalnog telopeptida kolagena tip I i vitamina D u serumu pre i tri meseca nakon uvođenja terapije. Sa povećanjem nivoa osteokalcina i ALP rastao je rizik za smanjenje mineralne gustine kostiju (BMD). Antiresorptivna terapija dovela je do značajnog smanjenja koncentracija C-terminalnog telopeptida (P lt 0,001) i osteokalcina (P lt 0,001). Tokom anaboličke terapije nivo osteokalcina je značajno porastao (P lt 0,01). Na početku studije 25,5% pacijentkinja je imalo optimalne koncentracije 25(OH)D u serumu, a tešku deficijenciju 17% žena. Nakon 3 meseca suplementacije većina je poboljšala status vitamina D (P lt 0,001). Naši rezultati ukazuju da određivanje osteokalcina i C-terminalnog telopeptida može biti korisno za predviđanje rizika za smanjenje BMD i praćenje efekata terapije osteoporoze. Takođe, potvrđena je važnost određivanja koncentracije 25(OH)D za procenu statusa vitamina D u osteoporozi, u cilju otkrivanja pacijenata sa insuficijencijom i utvrđivanja potrebe za suplementacijom.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Significance of bone biomarkers determination in the assessment of fracture risk and response to therapy in patients with osteoporosis, Značaj određivanja koštanih biomarkera u proceni rizika od fraktura i praćenju terapije kod pacijenata sa osteoporozom",
volume = "67",
number = "3",
pages = "196-208",
doi = "10.5937/arhfarm1703196M"
}
Milić, A., Đurić, M., Gajić, G., Mitrović, M., Urošević, L., Jovanović, V., Ješić, B., Kovačević, R., Vekić, J., Zeljković, A., Stefanović, A., Ninić, A.,& Spasojević-Kalimanovska, V.. (2017). Significance of bone biomarkers determination in the assessment of fracture risk and response to therapy in patients with osteoporosis. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 67(3), 196-208.
https://doi.org/10.5937/arhfarm1703196M
Milić A, Đurić M, Gajić G, Mitrović M, Urošević L, Jovanović V, Ješić B, Kovačević R, Vekić J, Zeljković A, Stefanović A, Ninić A, Spasojević-Kalimanovska V. Significance of bone biomarkers determination in the assessment of fracture risk and response to therapy in patients with osteoporosis. in Arhiv za farmaciju. 2017;67(3):196-208.
doi:10.5937/arhfarm1703196M .
Milić, Anđelka, Đurić, Milena, Gajić, Gordana, Mitrović, Milan, Urošević, Ljiljana, Jovanović, Veljko, Ješić, Budimir, Kovačević, Radmila, Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Ninić, Ana, Spasojević-Kalimanovska, Vesna, "Significance of bone biomarkers determination in the assessment of fracture risk and response to therapy in patients with osteoporosis" in Arhiv za farmaciju, 67, no. 3 (2017):196-208,
https://doi.org/10.5937/arhfarm1703196M . .

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB